{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:43:58Z","timestamp":1794779038067,"version":"4.9.1"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","award":["A-9181"],"award-info":[{"award-number":["A-9181"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS084298"],"award-info":[{"award-number":["R01NS084298"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS084298"],"award-info":[{"award-number":["R01NS084298"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HDSA Human Biology fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Huntington\u2019s disease (HD) is a devastating monogenic neurodegenerative disease characterized by early, selective pathology in the basal ganglia despite the ubiquitous expression of mutant huntingtin. The molecular mechanisms underlying this region-specific neuronal degeneration and how these relate to the development of early cognitive phenotypes are poorly understood. Here we show that there is selective loss of synaptic connections between the cortex and striatum in postmortem tissue from patients with HD that is associated with the increased activation and localization of complement proteins, innate immune molecules, to these synaptic elements. We also found that levels of these secreted innate immune molecules are elevated in the cerebrospinal fluid of premanifest HD patients and correlate with established measures of disease burden.<\/jats:p>\n                  <jats:p>In preclinical genetic models of HD, we show that complement proteins mediate the selective elimination of corticostriatal synapses at an early stage in disease pathogenesis, marking them for removal by microglia, the brain\u2019s resident macrophage population. This process requires mutant huntingtin to be expressed in both cortical and striatal neurons. Inhibition of this complement-dependent elimination mechanism through administration of a therapeutically relevant C1q function-blocking antibody or genetic ablation of a complement receptor on microglia prevented synapse loss, increased excitatory input to the striatum and rescued the early development of visual discrimination learning and cognitive flexibility deficits in these models. Together, our findings implicate microglia and the complement cascade in the selective, early degeneration of corticostriatal synapses and the development of cognitive deficits in presymptomatic HD; they also provide new preclinical data to support complement as a therapeutic target for early intervention.<\/jats:p>","DOI":"10.1038\/s41591-023-02566-3","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:01:56Z","timestamp":1696852916000},"page":"2866-2884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington\u2019s disease"],"prefix":"10.1038","volume":"29","author":[{"given":"Daniel K.","family":"Wilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly D.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Gergits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly Rose","family":"Willing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn B.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Frouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Daggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1850-6678","authenticated-orcid":false,"given":"Yejin A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L. M.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-9665","authenticated-orcid":false,"given":"Suman","family":"Jayadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Yednock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3705-7935","authenticated-orcid":false,"given":"X. William","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"2566_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204\u2013216 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"2566_CR2","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Prim. 1, 15005 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2566_CR3","doi-asserted-by":"crossref","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72, 971\u2013983 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"2566_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","volume":"69","author":"ZR Crook","year":"2011","unstructured":"Crook, Z. R. & Housman, D. Huntington\u2019s disease: can mice lead the way to treatment? Neuron 69, 423\u2013435 (2011).","journal-title":"Neuron"},{"key":"2566_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1242\/dmm.002451","volume":"2","author":"DE Ehrnhoefer","year":"2009","unstructured":"Ehrnhoefer, D. E., Butland, S. L., Pouladi, M. A. & Hayden, M. R. Mouse models of Huntington disease: variations on a theme. Dis. Model Mech. 2, 123\u2013129 (2009).","journal-title":"Dis. Model Mech."},{"key":"2566_CR6","doi-asserted-by":"publisher","first-page":"e0122335","DOI":"10.1371\/journal.pone.0122335","volume":"10","author":"AW Chan","year":"2015","unstructured":"Chan, A. W. et al. Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS ONE 10, e0122335 (2015).","journal-title":"PLoS ONE"},{"key":"2566_CR7","first-page":"2179","volume":"9","author":"R Chang","year":"2015","unstructured":"Chang, R., Liu, X., Li, S. & Li, X. J. Transgenic animal models for study of the pathogenesis of Huntington\u2019s disease and therapy. Drug Des. Dev. Ther. 9, 2179\u20132188 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"2566_CR8","doi-asserted-by":"publisher","first-page":"101970","DOI":"10.1016\/j.nicl.2019.101970","volume":"24","author":"FA Espinoza","year":"2019","unstructured":"Espinoza, F. A. et al. Resting-state fMRI dynamic functional network connectivity and associations with psychopathy traits. Neuroimage Clin. 24, 101970 (2019).","journal-title":"Neuroimage Clin."},{"key":"2566_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/brain.2017.0538","volume":"8","author":"FA Espinoza","year":"2018","unstructured":"Espinoza, F. A. et al. Whole-brain connectivity in a large study of Huntington\u2019s disease gene mutation carriers and healthy controls. Brain Connect 8, 166\u2013178 (2018).","journal-title":"Brain Connect"},{"key":"2566_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neuron.2005.03.025","volume":"46","author":"X Gu","year":"2005","unstructured":"Gu, X. et al. Pathological cell\u2013cell interactions elicited by a neuropathogenic form of mutant huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433\u2013444 (2005).","journal-title":"Neuron"},{"key":"2566_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1212\/WNL.44.5.823","volume":"44","author":"EH Aylward","year":"1994","unstructured":"Aylward, E. H. et al. Reduced basal ganglia volume associated with the gene for Huntington\u2019s disease in asymptomatic at-risk persons. Neurology 44, 823\u2013828 (1994).","journal-title":"Neurology"},{"key":"2566_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3174\/ajnr.A2018","volume":"31","author":"NZ Hobbs","year":"2010","unstructured":"Hobbs, N. Z. et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am. J. Neuroradiol. 31, 1036\u20131041 (2010).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2566_CR13","doi-asserted-by":"publisher","first-page":"e00033","DOI":"10.1042\/AN20090058","volume":"2","author":"C Cepeda","year":"2010","unstructured":"Cepeda, C., Cummings, D. M., Andre, V. M., Holley, S. M. & Levine, M. S. Genetic mouse models of Huntington\u2019s disease: focus on electrophysiological mechanisms. ASN Neuro 2, e00033 (2010).","journal-title":"ASN Neuro"},{"key":"2566_CR14","doi-asserted-by":"publisher","first-page":"RRN1182","DOI":"10.1371\/currents.RRN1182","volume":"2","author":"C Cepeda","year":"2010","unstructured":"Cepeda, C. et al. Rescuing the corticostriatal synaptic disconnection in the R6\/2 mouse model of Huntington\u2019s disease: exercise, adenosine receptors and ampakines. PLoS Curr. 2, RRN1182 (2010).","journal-title":"PLoS Curr."},{"key":"2566_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pneurobio.2006.11.001","volume":"81","author":"C Cepeda","year":"2007","unstructured":"Cepeda, C., Wu, N., Andre, V. M., Cummings, D. M. & Levine, M. S. The corticostriatal pathway in Huntington\u2019s disease. Prog. Neurobiol. 81, 253\u2013271 (2007).","journal-title":"Prog. Neurobiol."},{"key":"2566_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fneur.2018.00370","volume":"9","author":"J Lahr","year":"2018","unstructured":"Lahr, J. et al. Working memory-related effective connectivity in huntington\u2019s disease patients. Front. Neurol. 9, 370 (2018).","journal-title":"Front. Neurol."},{"key":"2566_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nn.4256","volume":"19","author":"P Langfelder","year":"2016","unstructured":"Langfelder, P. et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat. Neurosci. 19, 623\u2013633 (2016).","journal-title":"Nat. Neurosci."},{"key":"2566_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acn3.384","volume":"4","author":"P McColgan","year":"2017","unstructured":"McColgan, P. et al. White matter predicts functional connectivity in premanifest Huntington\u2019s disease. Ann. Clin. Transl. Neurol. 4, 106\u2013118 (2017).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2566_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nm.3514","volume":"20","author":"N Wang","year":"2014","unstructured":"Wang, N. et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease. Nat. Med. 20, 536\u2013541 (2014).","journal-title":"Nat. Med."},{"key":"2566_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2018.03.005","volume":"173","author":"S Yan","year":"2018","unstructured":"Yan, S. et al. A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. Cell 173, 989\u20131002 (2018).","journal-title":"Cell"},{"key":"2566_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","volume":"198","author":"LA Raymond","year":"2011","unstructured":"Raymond, L. A. et al. Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function. Neuroscience 198, 252\u2013273 (2011).","journal-title":"Neuroscience"},{"key":"2566_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.conb.2017.10.019","volume":"48","author":"MB Veldman","year":"2018","unstructured":"Veldman, M. B. & Yang, X. W. Molecular insights into cortico-striatal miscommunications in Huntington\u2019s disease. Curr. Opin. Neurobiol. 48, 79\u201389 (2018).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2566_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","volume":"33","author":"JL Plotkin","year":"2015","unstructured":"Plotkin, J. L. & Surmeier, D. J. Corticostriatal synaptic adaptations in Huntington\u2019s disease. Curr. Opin. Neurobiol. 33, 53\u201362 (2015).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2566_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/nn.4332","volume":"19","author":"H Hintiryan","year":"2016","unstructured":"Hintiryan, H. et al. The mouse cortico-striatal projectome. Nat. Neurosci. 19, 1100\u20131114 (2016).","journal-title":"Nat. Neurosci."},{"key":"2566_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1113\/jphysiol.2007.142448","volume":"585","author":"AJ Milnerwood","year":"2007","unstructured":"Milnerwood, A. J. & Raymond, L. A. Corticostriatal synaptic function in mouse models of Huntington\u2019s disease: early effects of huntingtin repeat length and protein load. J. Physiol. 585, 817\u2013831 (2007).","journal-title":"J. Physiol."},{"key":"2566_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nbd.2014.12.009","volume":"74","author":"GR Poudel","year":"2015","unstructured":"Poudel, G. R. et al. Longitudinal change in white matter microstructure in Huntington\u2019s disease: the IMAGE-HD study. Neurobiol. Dis. 74, 406\u2013412 (2015).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42\u201353 (2012).","journal-title":"Lancet Neurol."},{"key":"2566_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neulet.2012.02.095","volume":"514","author":"PG Unschuld","year":"2012","unstructured":"Unschuld, P. G. et al. Impaired cortico-striatal functional connectivity in prodromal Huntington\u2019s disease. Neurosci. Lett. 514, 204\u2013209 (2012).","journal-title":"Neurosci. Lett."},{"key":"2566_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58074-8","volume":"10","author":"P Polosecki","year":"2020","unstructured":"Polosecki, P. et al. Resting-state connectivity stratifies premanifest Huntington\u2019s disease by longitudinal cognitive decline rate. Sci. Rep. 10, 1252 (2020).","journal-title":"Sci. Rep."},{"key":"2566_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712\u2013716 (2016).","journal-title":"Science"},{"key":"2566_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature18283","volume":"534","author":"MJ Vasek","year":"2016","unstructured":"Vasek, M. J. et al. A complement\u2013microglial axis drives synapse loss during virus-induced memory impairment. Nature 534, 538\u2013543 (2016).","journal-title":"Nature"},{"key":"2566_CR32","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1084\/jem.20172244","volume":"215","author":"GT Norris","year":"2018","unstructured":"Norris, G. T. et al. Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury. J. Exp. Med. 215, 1789\u20131801 (2018).","journal-title":"J. Exp. Med."},{"key":"2566_CR33","doi-asserted-by":"publisher","first-page":"e15224","DOI":"10.7554\/eLife.15224","volume":"5","author":"DP Schafer","year":"2016","unstructured":"Schafer, D. P. et al. Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression. eLife 5, e15224 (2016).","journal-title":"eLife"},{"key":"2566_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic, B. et al. Changes in the synaptic proteome in tauopathy and rescue of Tau-induced synapse loss by C1q antibodies. Neuron 100, 1322\u20131336 (2018).","journal-title":"Neuron"},{"key":"2566_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","volume":"165","author":"H Lui","year":"2016","unstructured":"Lui, H. et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921\u2013935 (2016).","journal-title":"Cell"},{"key":"2566_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","volume":"52","author":"S Werneburg","year":"2020","unstructured":"Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 52, 167\u2013182 (2020).","journal-title":"Immunity"},{"key":"2566_CR37","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddw262","volume":"25","author":"JR Miller","year":"2016","unstructured":"Miller, J. R. et al. RNA-Seq of Huntington\u2019s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum. Mol. Genet 25, 2893\u20132904 (2016).","journal-title":"Hum. Mol. Genet"},{"key":"2566_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Trager","year":"2014","unstructured":"Trager, U. et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation. Brain 137, 819\u2013833 (2014).","journal-title":"Brain"},{"key":"2566_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.nbd.2014.10.012","volume":"73","author":"U Trager","year":"2015","unstructured":"Trager, U. et al. Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models. Neurobiol. Dis. 73, 388\u2013398 (2015).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep44849","volume":"7","author":"DJ Hensman Moss","year":"2017","unstructured":"Hensman Moss, D. J. et al. Huntington\u2019s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer\u2019s disease. Sci. Rep. 7, 44849 (2017).","journal-title":"Sci. Rep."},{"key":"2566_CR41","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai, Y. F. et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130, 1759\u20131766 (2007).","journal-title":"Brain"},{"key":"2566_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis, M. et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol. Dis. 83, 115\u2013121 (2015).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis, M. et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum. Brain Mapp. 32, 258\u2013270 (2011).","journal-title":"Hum. Brain Mapp."},{"key":"2566_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-63","volume":"6","author":"MC Oldham","year":"2012","unstructured":"Oldham, M. C., Langfelder, P. & Horvath, S. Network methods for describing sample relationships in genomic datasets: application to Huntington\u2019s disease. BMC Syst. Biol. 6, 63 (2012).","journal-title":"BMC Syst. Biol."},{"key":"2566_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.nbd.2011.09.003","volume":"45","author":"S Franciosi","year":"2012","unstructured":"Franciosi, S. et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 45, 438\u2013449 (2012).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161\u2013172 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2566_CR47","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/glia.20526","volume":"55","author":"DA Simmons","year":"2007","unstructured":"Simmons, D. A. et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington\u2019s disease. Glia 55, 1074\u20131084 (2007).","journal-title":"Glia"},{"key":"2566_CR48","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1172\/JCI64484","volume":"122","author":"W Kwan","year":"2012","unstructured":"Kwan, W. et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 122, 4737\u20134747 (2012).","journal-title":"J. Clin. Invest."},{"key":"2566_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","volume":"17","author":"A Crotti","year":"2014","unstructured":"Crotti, A. et al. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 17, 513\u2013521 (2014).","journal-title":"Nat. Neurosci."},{"key":"2566_CR50","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti, A. & Glass, C. K. The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol. 36, 364\u2013373 (2015).","journal-title":"Trends Immunol."},{"key":"2566_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01782-9","volume":"17","author":"JC Savage","year":"2020","unstructured":"Savage, J. C. et al. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington\u2019s disease pathology. J. Neuroinflammation 17, 98 (2020).","journal-title":"J. Neuroinflammation"},{"key":"2566_CR52","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.neuron.2020.06.021","volume":"107","author":"H Lee","year":"2020","unstructured":"Lee, H. et al. Cell type-specific transcriptomics reveals that mutant huntingtin leads to mitochondrial RNA release and neuronal innate immune activation. Neuron 107, 891\u2013908 (2020).","journal-title":"Neuron"},{"key":"2566_CR53","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.nbd.2020.104963","volume":"143","author":"DK Wilton","year":"2020","unstructured":"Wilton, D. K. & Stevens, B. The contribution of glial cells to Huntington\u2019s disease pathogenesis. Neurobiol. Dis. 143, 104963 (2020).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/exnr.1999.7170","volume":"159","author":"SK Singhrao","year":"1999","unstructured":"Singhrao, S. K., Neal, J. W., Morgan, B. P. & Gasque, P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease. Exp. Neurol. 159, 362\u2013376 (1999).","journal-title":"Exp. Neurol."},{"key":"2566_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0581-9","volume":"12","author":"F Agus","year":"2019","unstructured":"Agus, F., Crespo, D., Myers, R. H. & Labadorf, A. The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington\u2019s disease brain. BMC Med. Genomics 12, 137 (2019).","journal-title":"BMC Med. Genomics"},{"key":"2566_CR56","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges, A. et al. Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum. Mol. Genet 15, 965\u2013977 (2006).","journal-title":"Hum. Mol. Genet"},{"key":"2566_CR57","doi-asserted-by":"publisher","first-page":"e0143563","DOI":"10.1371\/journal.pone.0143563","volume":"10","author":"A Labadorf","year":"2015","unstructured":"Labadorf, A. et al. RNA sequence analysis of human Huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS ONE 10, e0143563 (2015).","journal-title":"PLoS ONE"},{"key":"2566_CR58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/mds.25026","volume":"27","author":"JA Pillai","year":"2012","unstructured":"Pillai, J. A. et al. Clinical severity of Huntington\u2019s disease does not always correlate with neuropathologic stage. Mov. Disord. 27, 1099\u20131103 (2012).","journal-title":"Mov. Disord."},{"key":"2566_CR59","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel, J. P. et al. Neuropathological classification of Huntington\u2019s disease. J. Neuropathol. Exp. Neurol. 44, 559\u2013577 (1985).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2566_CR60","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1523\/JNEUROSCI.11-12-03877.1991","volume":"11","author":"RJ Ferrante","year":"1991","unstructured":"Ferrante, R. J., Kowall, N. W. & Richardson, E. P. Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington\u2019s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11, 3877\u20133887 (1991).","journal-title":"J. Neurosci."},{"key":"2566_CR61","first-page":"938530","volume":"2014","author":"C Fourie","year":"2014","unstructured":"Fourie, C. et al. Differential changes in postsynaptic density proteins in postmortem Huntington\u2019s disease and Parkinson\u2019s disease human brains. J. Neurodegener. Dis. 2014, 938530 (2014).","journal-title":"J. Neurodegener. Dis."},{"key":"2566_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","volume":"19","author":"ES Reis","year":"2019","unstructured":"Reis, E. S., Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. New insights into the immune functions of complement. Nat. Rev. Immunol. 19, 503\u2013516 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2566_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris, M. & Remuzzi, G. Overview of complement activation and regulation. Semin. Nephrol. 33, 479\u2013492 (2013).","journal-title":"Semin. Nephrol."},{"key":"2566_CR64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1006\/exnr.1998.6919","volume":"154","author":"GM Halliday","year":"1998","unstructured":"Halliday, G. M. et al. Regional specificity of brain atrophy in Huntington\u2019s disease. Exp. Neurol. 154, 663\u2013672 (1998).","journal-title":"Exp. Neurol."},{"key":"2566_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0022-510X(93)90187-4","volume":"119","author":"M Wakai","year":"1993","unstructured":"Wakai, M., Takahashi, A. & Hashizume, Y. A histometrical study on the globus pallidus in Huntington\u2019s disease. J. Neurol. Sci. 119, 18\u201327 (1993).","journal-title":"J. Neurol. Sci."},{"key":"2566_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bpa.12429","volume":"26","author":"MK Singh-Bains","year":"2016","unstructured":"Singh-Bains, M. K., Waldvogel, H. J. & Faull, R. L. The role of the human globus pallidus in Huntington\u2019s disease. Brain Pathol. 26, 741\u2013751 (2016).","journal-title":"Brain Pathol."},{"key":"2566_CR67","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/cne.23235","volume":"521","author":"W Lei","year":"2013","unstructured":"Lei, W. et al. Confocal laser scanning microscopy and ultrastructural study of VGLUT2 thalamic input to striatal projection neurons in rats. J. Comp. Neurol. 521, 1354\u20131377 (2013).","journal-title":"J. Comp. Neurol."},{"key":"2566_CR68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/cne.21099","volume":"499","author":"DV Raju","year":"2006","unstructured":"Raju, D. V., Shah, D. J., Wright, T. M., Hall, R. A. & Smith, Y. Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats. J. Comp. Neurol. 499, 231\u2013243 (2006).","journal-title":"J. Comp. Neurol."},{"key":"2566_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nn.3003","volume":"15","author":"JB Ding","year":"2011","unstructured":"Ding, J. B., Oh, W. J., Sabatini, B. L. & Gu, C. Semaphorin 3E-Plexin-D1 signaling controls pathway-specific synapse formation in the striatum. Nat. Neurosci. 15, 215\u2013223 (2011).","journal-title":"Nat. Neurosci."},{"key":"2566_CR70","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182\u20136195 (2008).","journal-title":"J. Neurosci."},{"key":"2566_CR71","doi-asserted-by":"publisher","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","volume":"7","author":"LB Menalled","year":"2012","unstructured":"Menalled, L. B. et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175. PLoS ONE 7, e49838 (2012).","journal-title":"PLoS ONE"},{"key":"2566_CR72","doi-asserted-by":"publisher","first-page":"e50717","DOI":"10.1371\/journal.pone.0050717","volume":"7","author":"T Heikkinen","year":"2012","unstructured":"Heikkinen, T. et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease. PLoS ONE 7, e50717 (2012).","journal-title":"PLoS ONE"},{"key":"2566_CR73","doi-asserted-by":"publisher","first-page":"e0123527","DOI":"10.1371\/journal.pone.0123527","volume":"10","author":"N Carty","year":"2015","unstructured":"Carty, N. et al. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington\u2019s disease: an in vivo high-content imaging study. PLoS ONE 10, e0123527 (2015).","journal-title":"PLoS ONE"},{"key":"2566_CR74","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1152\/jn.01056.2014","volume":"113","author":"T Indersmitten","year":"2015","unstructured":"Indersmitten, T., Tran, C. H., Cepeda, C. & Levine, M. S. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington\u2019s disease. J. Neurophysiol. 113, 2953\u20132966 (2015).","journal-title":"J. Neurophysiol."},{"key":"2566_CR75","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","volume":"83","author":"JL Plotkin","year":"2014","unstructured":"Plotkin, J. L. et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease. Neuron 83, 178\u2013188 (2014).","journal-title":"Neuron"},{"key":"2566_CR76","doi-asserted-by":"publisher","first-page":"tgaa044","DOI":"10.1093\/texcom\/tgaa044","volume":"1","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. Abnormal brain development in Huntington\u2019 disease is recapitulated in the zQ175 knock-in mouse model. Cereb. Cortex Commun. 1, tgaa044 (2020).","journal-title":"Cereb. Cortex Commun."},{"key":"2566_CR77","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","volume":"92","author":"V Beaumont","year":"2016","unstructured":"Beaumont, V. et al. Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models. Neuron 92, 1220\u20131237 (2016).","journal-title":"Neuron"},{"key":"2566_CR78","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1172\/JCI120616","volume":"129","author":"E Vezzoli","year":"2019","unstructured":"Vezzoli, E. et al. Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington\u2019s disease. J. Clin. Invest. 129, 2390\u20132403 (2019).","journal-title":"J. Clin. Invest."},{"key":"2566_CR79","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.1523\/JNEUROSCI.4699-13.2014","volume":"34","author":"SU McKinstry","year":"2014","unstructured":"McKinstry, S. U. et al. Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J. Neurosci. 34, 9455\u20139472 (2014).","journal-title":"J. Neurosci."},{"key":"2566_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0169-328X(00)00194-7","volume":"83","author":"S Hisano","year":"2000","unstructured":"Hisano, S. et al. Regional expression of a gene encoding a neuron-specific Na+-dependent inorganic phosphate cotransporter (DNPI) in the rat forebrain. Brain Res. Mol. Brain Res. 83, 34\u201343 (2000).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"2566_CR81","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0896-6273(01)00344-0","volume":"31","author":"RT Fremeau Jr.","year":"2001","unstructured":"Fremeau, R. T. Jr. et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron 31, 247\u2013260 (2001).","journal-title":"Neuron"},{"key":"2566_CR82","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tins.2003.11.005","volume":"27","author":"RT Fremeau Jr.","year":"2004","unstructured":"Fremeau, R. T. Jr., Voglmaier, S., Seal, R. P. & Edwards, R. H. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci. 27, 98\u2013103 (2004).","journal-title":"Trends Neurosci."},{"key":"2566_CR83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cne.20444","volume":"483","author":"EE Hur","year":"2005","unstructured":"Hur, E. E. & Zaborszky, L. Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization study [corrected]. J. Comp. Neurol. 483, 351\u2013373 (2005).","journal-title":"J. Comp. Neurol."},{"key":"2566_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/jnen\/63.1.20","volume":"63","author":"JJ Bacci","year":"2004","unstructured":"Bacci, J. J., Kachidian, P., Kerkerian-Le Goff, L. & Salin, P. Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J. Neuropathol. Exp. Neurol. 63, 20\u201331 (2004).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2566_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nbd.2017.07.020","volume":"108","author":"A Parievsky","year":"2017","unstructured":"Parievsky, A. et al. Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol. Dis. 108, 29\u201344 (2017).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnsys.2014.00198","volume":"8","author":"YP Deng","year":"2014","unstructured":"Deng, Y. P., Wong, T., Wan, J. Y. & Reiner, A. Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington\u2019s disease. Front. Syst. Neurosci. 8, 198 (2014).","journal-title":"Front. Syst. Neurosci."},{"key":"2566_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2018.03.003","volume":"98","author":"JC Octeau","year":"2018","unstructured":"Octeau, J. C. et al. An optical neuron-astrocyte proximity assay at synaptic distance scales. Neuron 98, 49\u201366 (2018).","journal-title":"Neuron"},{"key":"2566_CR88","doi-asserted-by":"publisher","first-page":"20130134","DOI":"10.1098\/rstb.2013.0134","volume":"369","author":"CE Taft","year":"2014","unstructured":"Taft, C. E. & Turrigiano, G. G. PSD-95 promotes the stabilization of young synaptic contacts. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369, 20130134 (2014).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2566_CR89","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00415-010-5768-0","volume":"258","author":"SJ van den Bogaard","year":"2011","unstructured":"van den Bogaard, S. J. et al. Early atrophy of pallidum and accumbens nucleus in Huntington\u2019s disease. J. Neurol. 258, 412\u2013420 (2011).","journal-title":"J. Neurol."},{"key":"2566_CR90","volume":"14","author":"MI Fonseca","year":"2017","unstructured":"Fonseca, M. I. et al. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. lammation 14, 48 (2017).","journal-title":"lammation"},{"key":"2566_CR91","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2018.07.028","volume":"174","author":"A Saunders","year":"2018","unstructured":"Saunders, A. et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015\u20131030 (2018).","journal-title":"Cell"},{"key":"2566_CR92","doi-asserted-by":"publisher","first-page":"104950","DOI":"10.1016\/j.nbd.2020.104950","volume":"141","author":"E Sapp","year":"2020","unstructured":"Sapp, E. et al. Protein changes in synaptosomes of Huntington\u2019s disease knock-in mice are dependent on age and brain region. Neurobiol. Dis. 141, 104950 (2020).","journal-title":"Neurobiol. Dis."},{"key":"2566_CR93","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/j.celrep.2018.02.004","volume":"22","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. Noninflammatory changes of microglia are sufficient to cause epilepsy. Cell Rep. 22, 2080\u20132093 (2018).","journal-title":"Cell Rep."},{"key":"2566_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fncel.2019.00090","volume":"13","author":"F Reichert","year":"2019","unstructured":"Reichert, F. & Rotshenker, S. Galectin-3 (MAC-2) controls microglia phenotype whether amoeboid and phagocytic or branched and non-phagocytic by regulating the cytoskeleton. Front. Cell Neurosci. 13, 90 (2019).","journal-title":"Front. Cell Neurosci."},{"key":"2566_CR95","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","volume":"74","author":"DP Schafer","year":"2012","unstructured":"Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691\u2013705 (2012).","journal-title":"Neuron"},{"key":"2566_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43024-w","volume":"9","author":"J Burgold","year":"2019","unstructured":"Burgold, J. et al. Cortical circuit alterations precede motor impairments in Huntington\u2019s disease mice. Sci. Rep. 9, 6634 (2019).","journal-title":"Sci. Rep."},{"key":"2566_CR97","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.biopsych.2008.12.026","volume":"65","author":"S Schippling","year":"2009","unstructured":"Schippling, S. et al. Abnormal motor cortex excitability in preclinical and very early Huntington\u2019s disease. Biol. Psychiatry 65, 959\u2013965 (2009).","journal-title":"Biol. Psychiatry"},{"key":"2566_CR98","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/glia.10293","volume":"44","author":"Y Sasaki","year":"2003","unstructured":"Sasaki, Y. et al. Selective expression of Gi\/o-coupled ATP receptor P2Y12 in microglia in rat brain. Glia 44, 242\u2013250 (2003).","journal-title":"Glia"},{"key":"2566_CR99","doi-asserted-by":"publisher","first-page":"E1738","DOI":"10.1073\/pnas.1525528113","volume":"113","author":"ML Bennett","year":"2016","unstructured":"Bennett, M. L. et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl Acad. Sci. USA 113, E1738\u2013E1746 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR100","doi-asserted-by":"crossref","unstructured":"Schafer, D. P., Lehrman, E. K., Heller, C. T. & Stevens, B. An engulfment assay: a protocol to assess interactions between CNS phagocytes and neurons. J. Vis. Exp. 51482 (2014).","DOI":"10.3791\/51482"},{"key":"2566_CR101","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1523\/JNEUROSCI.23-06-02170.2003","volume":"23","author":"T Ebihara","year":"2003","unstructured":"Ebihara, T., Kawabata, I., Usui, S., Sobue, K. & Okabe, S. Synchronized formation and remodeling of postsynaptic densities: long-term visualization of hippocampal neurons expressing postsynaptic density proteins tagged with green fluorescent protein. J. Neurosci. 23, 2170\u20132181 (2003).","journal-title":"J. Neurosci."},{"key":"2566_CR102","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature12776","volume":"504","author":"WS Chung","year":"2013","unstructured":"Chung, W. S. et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394\u2013400 (2013).","journal-title":"Nature"},{"key":"2566_CR103","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nn.3691","volume":"17","author":"X Tong","year":"2014","unstructured":"Tong, X. et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington\u2019s disease model mice. Nat. Neurosci. 17, 694\u2013703 (2014).","journal-title":"Nat. Neurosci."},{"key":"2566_CR104","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1523\/JNEUROSCI.3693-15.2016","volume":"36","author":"R Jiang","year":"2016","unstructured":"Jiang, R., Diaz-Castro, B., Looger, L. L. & Khakh, B. S. Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington\u2019s disease model mice. J. Neurosci. 36, 3453\u20133470 (2016).","journal-title":"J. Neurosci."},{"key":"2566_CR105","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tins.2017.05.002","volume":"40","author":"BS Khakh","year":"2017","unstructured":"Khakh, B. S. et al. Unravelling and exploiting astrocyte dysfunction in Huntington\u2019s disease. Trends Neurosci. 40, 422\u2013437 (2017).","journal-title":"Trends Neurosci."},{"key":"2566_CR106","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1073\/pnas.0911503106","volume":"106","author":"J Bradford","year":"2009","unstructured":"Bradford, J. et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl Acad. Sci. USA 106, 22480\u201322485 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR107","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.neuron.2015.02.026","volume":"85","author":"B Huang","year":"2015","unstructured":"Huang, B. et al. Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron 85, 1212\u20131226 (2015).","journal-title":"Neuron"},{"key":"2566_CR108","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/hmg\/ddz009","volume":"28","author":"TL Petkau","year":"2019","unstructured":"Petkau, T. L. et al. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington\u2019s disease-like phenotype in BACHD mice. Hum. Mol. Genet. 28, 1661\u20131670 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2566_CR109","first-page":"487","volume":"28","author":"TE Wood","year":"2019","unstructured":"Wood, T. E. et al. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington\u2019s disease mouse model. Hum. Mol. Genet. 28, 487\u2013500 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2566_CR110","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","volume":"19","author":"M Faideau","year":"2010","unstructured":"Faideau, M. et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington\u2019s disease subjects. Hum. Mol. Genet. 19, 3053\u20133067 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"2566_CR111","doi-asserted-by":"publisher","first-page":"9622","DOI":"10.1073\/pnas.1818042116","volume":"116","author":"C Ferrari Bardile","year":"2019","unstructured":"Ferrari Bardile, C. et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc. Natl Acad. Sci. USA 116, 9622\u20139627 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR112","doi-asserted-by":"publisher","first-page":"46974","DOI":"10.1074\/jbc.M307764200","volume":"278","author":"C Gaboriaud","year":"2003","unstructured":"Gaboriaud, C. et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 278, 46974\u201346982 (2003).","journal-title":"J. Biol. Chem."},{"key":"2566_CR113","doi-asserted-by":"publisher","first-page":"13916","DOI":"10.1073\/pnas.1311113110","volume":"110","author":"U Venkatraman Girija","year":"2013","unstructured":"Venkatraman Girija, U. et al. Structural basis of the C1q\/C1s interaction and its central role in assembly of the C1 complex of complement activation. Proc. Natl Acad. Sci. USA 110, 13916\u201313920 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR114","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1073\/pnas.1718709115","volume":"115","author":"JOM Almitairi","year":"2018","unstructured":"Almitairi, J. O. M. et al. Structure of the C1r\u2013C1s interaction of the C1 complex of complement activation. Proc. Natl Acad. Sci. USA 115, 768\u2013773 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR115","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.celrep.2019.11.013","volume":"29","author":"A Vukojicic","year":"2019","unstructured":"Vukojicic, A. et al. The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep. 29, 3087\u20133100 (2019).","journal-title":"Cell Rep."},{"key":"2566_CR116","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1091581817740873","volume":"36","author":"JA Lansita","year":"2017","unstructured":"Lansita, J. A. et al. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int. J. Toxicol. 36, 449\u2013462 (2017).","journal-title":"Int. J. Toxicol."},{"key":"2566_CR117","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo, J. F., Curran, G. L. & Berg, C. T. Macromolecular permeability across the blood\u2013nerve and blood\u2013brain barriers. Proc. Natl Acad. Sci. USA 91, 5705\u20135709 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2566_CR118","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","volume":"89","author":"YJ Zuchero","year":"2016","unstructured":"Zuchero, Y. J. et al. Discovery of novel blood\u2013brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron 89, 70\u201382 (2016).","journal-title":"Neuron"},{"key":"2566_CR119","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cortex.2019.10.015","volume":"123","author":"S Martinez-Horta","year":"2020","unstructured":"Martinez-Horta, S. et al. Impaired face-like object recognition in premanifest Huntington\u2019s disease. Cortex 123, 162\u2013172 (2020).","journal-title":"Cortex"},{"key":"2566_CR120","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill, R. I. et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s Disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 19, 502\u2013512 (2020).","journal-title":"Lancet Neurol."},{"key":"2566_CR121","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/jnnp-2020-324104","volume":"92","author":"C Langley","year":"2021","unstructured":"Langley, C. et al. Fronto-striatal circuits for cognitive flexibility in far from onset Huntington\u2019s disease: evidence from the Young Adult Study. J. Neurol. Neurosurg. Psychiatry 92, 143\u2013149 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2566_CR122","first-page":"361","volume":"9","author":"PC Curtin","year":"2015","unstructured":"Curtin, P. C. et al. Cognitive training at a young age attenuates deficits in the zQ175 mouse model of HD. Front. Behav. Neurosci. 9, 361 (2015).","journal-title":"Front. Behav. Neurosci."},{"key":"2566_CR123","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fnbeh.2018.00226","volume":"12","author":"TO Piiponniemi","year":"2018","unstructured":"Piiponniemi, T. O. et al. Impaired performance of the Q175 mouse model of Huntington\u2019s disease in the Touch Screen Paired Associates Learning Task. Front. Behav. Neurosci. 12, 226 (2018).","journal-title":"Front. Behav. Neurosci."},{"key":"2566_CR124","doi-asserted-by":"publisher","unstructured":"Oakeshott, S. et al. Deficits in a simple visual go\/no-go discrimination task in two mouse models of Huntington\u2019s disease. PLoS Curr. 5, https:\/\/doi.org\/10.1371\/currents.hd.fe74c94bdd446a0470f6f905a30b5dd1 (2013).","DOI":"10.1371\/currents.hd.fe74c94bdd446a0470f6f905a30b5dd1"},{"key":"2566_CR125","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/cne.25023","volume":"529","author":"Y Deng","year":"2021","unstructured":"Deng, Y., Wang, H., Joni, M., Sekhri, R. & Reiner, A. Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington\u2019s disease mice. J. Comp. Neurol. 529, 1327\u20131371 (2021).","journal-title":"J. Comp. Neurol."},{"key":"2566_CR126","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/npp.2012.57","volume":"37","author":"JJ Luykx","year":"2012","unstructured":"Luykx, J. J. et al. A common variant in ERBB4 regulates GABA concentrations in human cerebrospinal fluid. Neuropsychopharmacology 37, 2088\u20132092 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"2566_CR127","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","volume":"310","author":"H Reiber","year":"2001","unstructured":"Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 310, 173\u2013186 (2001).","journal-title":"Clin. Chim. Acta"},{"key":"2566_CR128","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1074\/mcp.M900513-MCP200","volume":"9","author":"E Mouton-Barbosa","year":"2010","unstructured":"Mouton-Barbosa, E. et al. In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol. Cell. Proteomics 9, 1006\u20131021 (2010).","journal-title":"Mol. Cell. Proteomics"},{"key":"2566_CR129","doi-asserted-by":"publisher","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","volume":"6","author":"L Higginbotham","year":"2020","unstructured":"Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci. Adv. 6, eaaz9360 (2020).","journal-title":"Sci. Adv."},{"key":"2566_CR130","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1074\/mcp.M800231-MCP200","volume":"8","author":"Q Fang","year":"2009","unstructured":"Fang, Q. et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell. Proteomics 8, 451\u2013466 (2009).","journal-title":"Mol. Cell. Proteomics"},{"key":"2566_CR131","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi, S. J. et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8, 791\u2013801 (2009).","journal-title":"Lancet Neurol."},{"key":"2566_CR132","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol. 16, 601\u2013609 (2017).","journal-title":"Lancet Neurol."},{"key":"2566_CR133","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/hbm.21348","volume":"33","author":"RC Wolf","year":"2012","unstructured":"Wolf, R. C. et al. Brain activation and functional connectivity in premanifest Huntington\u2019s disease during states of intrinsic and phasic alertness. Hum. Brain Mapp. 33, 2161\u20132173 (2012).","journal-title":"Hum. Brain Mapp."},{"key":"2566_CR134","first-page":"1715","volume":"25","author":"JS Paulsen","year":"2004","unstructured":"Paulsen, J. S. et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington\u2019s disease. AJNR Am. J. Neuroradiol. 25, 1715\u20131721 (2004).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2566_CR135","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn, D. R., Hayden, M. R.Paulsen, J. S. & PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 397\u2013408 (2010).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"2566_CR136","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/jnnp-2011-301732","volume":"83","author":"DL Harrington","year":"2012","unstructured":"Harrington, D. L. et al. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 83, 612\u2013619 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2566_CR137","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.nicl.2016.02.014","volume":"11","author":"AV Faria","year":"2016","unstructured":"Faria, A. V. et al. Linking white matter and deep gray matter alterations in premanifest Huntington disease. Neuroimage Clin. 11, 450\u2013460 (2016).","journal-title":"Neuroimage Clin."},{"key":"2566_CR138","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fnins.2016.00197","volume":"10","author":"OR Phillips","year":"2016","unstructured":"Phillips, O. R. et al. Major superficial white matter abnormalities in Huntington\u2019s disease. Front. Neurosci. 10, 197 (2016).","journal-title":"Front. Neurosci."},{"key":"2566_CR139","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jnr.24358","volume":"97","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. Altered brain iron content and deposition rate in Huntington\u2019s disease as indicated by quantitative susceptibility MRI. J. Neurosci. Res. 97, 467\u2013479 (2019).","journal-title":"J. Neurosci. Res."},{"key":"2566_CR140","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/psp4.12097","volume":"5","author":"JH Warner","year":"2016","unstructured":"Warner, J. H. & Sampaio, C. Modeling variability in the progression of Huntington\u2019s disease a novel modeling approach applied to structural imaging markers from TRACK-HD. CPT Pharmacomet. Syst. Pharm. 5, 437\u2013445 (2016).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"2566_CR141","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajmg.b.31232","volume":"156B","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 751\u2013763 (2011).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"2566_CR142","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3174\/ajnr.A4617","volume":"37","author":"JM van Bergen","year":"2016","unstructured":"van Bergen, J. M. et al. Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington disease. AJNR Am. J. Neuroradiol. 37, 789\u2013796 (2016).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2566_CR143","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41586-020-2277-x","volume":"582","author":"N Kamitaki","year":"2020","unstructured":"Kamitaki, N. et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577\u2013581 (2020).","journal-title":"Nature"},{"key":"2566_CR144","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-012-0797-8","volume":"119","author":"J Daborg","year":"2012","unstructured":"Daborg, J. et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer\u2019s disease. J. Neural Transm. (Vienna) 119, 789\u2013797 (2012).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"2566_CR145","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa, M. et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front. Immunol. 9, 2664 (2018).","journal-title":"Front. Immunol."},{"key":"2566_CR146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jcla.10095","volume":"18","author":"RF Ritchie","year":"2004","unstructured":"Ritchie, R. F., Palomaki, G. E., Neveux, L. M. & Navolotskaia, O. Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world\u2019s literature. J. Clin. Lab. Anal. 18, 9\u201313 (2004).","journal-title":"J. Clin. Lab. Anal."},{"key":"2566_CR147","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1021\/pr0700753","volume":"6","author":"A Dalrymple","year":"2007","unstructured":"Dalrymple, A. et al. Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833\u20132840 (2007).","journal-title":"J. Proteome Res."},{"key":"2566_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.36","volume":"5","author":"L Ping","year":"2018","unstructured":"Ping, L. et al. Global quantitative analysis of the human brain proteome in Alzheimer\u2019s and Parkinson\u2019s disease. Sci. Data 5, 180036 (2018).","journal-title":"Sci. Data"},{"key":"2566_CR149","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.neuron.2018.10.031","volume":"100","author":"A Litvinchuk","year":"2018","unstructured":"Litvinchuk, A. et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer\u2019s disease. Neuron 100, 1337\u20131353 (2018).","journal-title":"Neuron"},{"key":"2566_CR150","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","volume":"28","author":"T Wu","year":"2019","unstructured":"Wu, T. et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 28, 2111\u20132123 (2019).","journal-title":"Cell Rep."},{"key":"2566_CR151","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","volume":"183","author":"MI Fonseca","year":"2009","unstructured":"Fonseca, M. I. et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer\u2019s disease. J. Immunol. 183, 1375\u20131383 (2009).","journal-title":"J. Immunol."},{"key":"2566_CR152","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1523\/JNEUROSCI.0435-08.2008","volume":"28","author":"J Ding","year":"2008","unstructured":"Ding, J., Peterson, J. D. & Surmeier, D. J. Corticostriatal and thalamostriatal synapses have distinctive properties. J. Neurosci. 28, 6483\u20136492 (2008).","journal-title":"J. Neurosci."},{"key":"2566_CR153","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuron.2018.09.017","volume":"100","author":"EK Lehrman","year":"2018","unstructured":"Lehrman, E. K. et al. CD47 protects synapses from excess microglia-mediated pruning during development. Neuron 100, 120\u2013134 (2018).","journal-title":"Neuron"},{"key":"2566_CR154","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1523\/JNEUROSCI.2812-14.2015","volume":"35","author":"AM Estrada-Sanchez","year":"2015","unstructured":"Estrada-Sanchez, A. M. et al. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington\u2019s disease. J. Neurosci. 35, 4440\u20134451 (2015).","journal-title":"J. Neurosci."},{"key":"2566_CR155","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0166-4328(03)00218-3","volume":"150","author":"RE Featherstone","year":"2004","unstructured":"Featherstone, R. E. & McDonald, R. J. Dorsal striatum and stimulus-response learning: lesions of the dorsolateral, but not dorsomedial, striatum impair acquisition of a simple discrimination task. Behav. Brain Res. 150, 15\u201323 (2004).","journal-title":"Behav. Brain Res."},{"key":"2566_CR156","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/brain\/awz363","volume":"143","author":"JD Crapser","year":"2020","unstructured":"Crapser, J. D. et al. Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington\u2019s disease. Brain 143, 266\u2013288 (2020).","journal-title":"Brain"},{"key":"2566_CR157","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164\u20131178 (2007).","journal-title":"Cell"},{"key":"2566_CR158","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000012969","volume":"98","author":"A Delva","year":"2022","unstructured":"Delva, A., Michiels, L., Koole, M., Van Laere, K. & Vandenberghe, W. Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study. Neurology 98, e83\u2013e94 (2022).","journal-title":"Neurology"},{"key":"2566_CR159","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","volume":"97","author":"P Zeun","year":"2019","unstructured":"Zeun, P., Scahill, R. I., Tabrizi, S. J. & Wild, E. J. Fluid and imaging biomarkers for Huntington\u2019s disease. Mol. Cell. Neurosci. 97, 67\u201380 (2019).","journal-title":"Mol. Cell. Neurosci."},{"key":"2566_CR160","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JHD-170273","volume":"7","author":"E Silajdzic","year":"2018","unstructured":"Silajdzic, E. & Bjorkqvist, M. A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward. J. Huntingtons Dis. 7, 109\u2013135 (2018).","journal-title":"J. Huntingtons Dis."},{"key":"2566_CR161","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl. Med. 10, eaat7108 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2566_CR162","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1074-7613(00)80278-2","volume":"5","author":"A Coxon","year":"1996","unstructured":"Coxon, A. et al. A novel role for the \u03b22 integrin CD11b\/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5, 653\u2013666 (1996).","journal-title":"Immunity"},{"key":"2566_CR163","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2144\/00291bm09","volume":"29","author":"GE Truett","year":"2000","unstructured":"Truett, G. E. et al. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 29, 52 (2000).","journal-title":"Biotechniques"},{"key":"2566_CR164","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.25171","volume":"83","author":"SL Mason","year":"2018","unstructured":"Mason, S. L. et al. Predicting clinical diagnosis in Huntington\u2019s disease: an imaging polymarker. Ann. Neurol. 83, 532\u2013543 (2018).","journal-title":"Ann. Neurol."},{"key":"2566_CR165","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn, D. R. et al. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin. Genet. 65, 267\u2013277 (2004).","journal-title":"Clin. Genet."},{"key":"2566_CR166","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","volume":"33","author":"G Fanali","year":"2012","unstructured":"Fanali, G. et al. Human serum albumin: from bench to bedside. Mol. Asp. Med 33, 209\u2013290 (2012).","journal-title":"Mol. Asp. Med"},{"key":"2566_CR167","doi-asserted-by":"crossref","unstructured":"Frick, E. & Scheid-Seydel, L. [Exchange processes between plasma and cerebrospinal fluid examined with radio-iodine labeled albumin]. Klin. Wochenschr. 36, 66\u201369 (1958).","DOI":"10.1007\/BF01486246"},{"key":"2566_CR168","unstructured":"Hofmann, G. & Leupold-Lowenthal, H. [Studies on the blood-brain and the blood-cerebrospinal fluid barrier. I. Penetration of radioiodine labeled albumin into the choroid plexus]. Wien. Z. Nervenheilkd. Grenzgeb. 12, 165\u2013170 (1955)."},{"key":"2566_CR169","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1152\/ajplegacy.1953.175.1.96","volume":"175","author":"RA Fishman","year":"1953","unstructured":"Fishman, R. A. Exchange of albumin between plasma and cerebrospinal fluid. Am. J. Physiol. 175, 96\u201398 (1953).","journal-title":"Am. J. Physiol."},{"key":"2566_CR170","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1523\/JNEUROSCI.02-10-01507.1982","volume":"2","author":"JF Poduslo","year":"1982","unstructured":"Poduslo, J. F. et al. Altered blood\u2013nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J. Neurosci. 2, 1507\u20131514 (1982).","journal-title":"J. Neurosci."},{"key":"2566_CR171","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2003.12.002","volume":"219","author":"S Seyfert","year":"2004","unstructured":"Seyfert, S., Faulstich, A. & Marx, P. What determines the CSF concentrations of albumin and plasma-derived IgG? J. Neurol. Sci. 219, 31\u201333 (2004).","journal-title":"J. Neurol. Sci."},{"key":"2566_CR172","doi-asserted-by":"publisher","first-page":"e15809","DOI":"10.1371\/journal.pone.0015809","volume":"6","author":"YC Huang","year":"2011","unstructured":"Huang, Y. C. et al. Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington\u2019s disease. PLoS ONE 6, e15809 (2011).","journal-title":"PLoS ONE"},{"key":"2566_CR173","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bpa.12426","volume":"26","author":"U Rub","year":"2016","unstructured":"Rub, U. et al. Huntington\u2019s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 26, 726\u2013740 (2016).","journal-title":"Brain Pathol."},{"key":"2566_CR174","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","volume":"4","author":"R McGonigal","year":"2016","unstructured":"McGonigal, R. et al. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathol. Commun. 4, 23 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"2566_CR175","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-018-0278-0","volume":"13","author":"H Jiao","year":"2018","unstructured":"Jiao, H. et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol. Neurodegener. 13, 45 (2018).","journal-title":"Mol. Neurodegener."},{"key":"2566_CR176","doi-asserted-by":"publisher","first-page":"eabj2685","DOI":"10.1126\/science.abj2685","volume":"373","author":"SS Holden","year":"2021","unstructured":"Holden, S. S. et al. Complement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury. Science 373, eabj2685 (2021).","journal-title":"Science"},{"key":"2566_CR177","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","volume":"597","author":"M Absinta","year":"2021","unstructured":"Absinta, M. et al. A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis. Nature 597, 709\u2013714 (2021).","journal-title":"Nature"},{"key":"2566_CR178","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/nn.4123","volume":"18","author":"S Pluta","year":"2015","unstructured":"Pluta, S. et al. A direct translaminar inhibitory circuit tunes cortical output. Nat. Neurosci. 18, 1631\u20131640 (2015).","journal-title":"Nat. Neurosci."},{"key":"2566_CR179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneumeth.2016.05.015","volume":"269","author":"J Merel","year":"2016","unstructured":"Merel, J., Shababo, B., Naka, A., Adesnik, H. & Paninski, L. Bayesian methods for event analysis of intracellular currents. J. Neurosci. Methods 269, 21\u201332 (2016).","journal-title":"J. Neurosci. Methods"},{"key":"2566_CR180","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1749-6632.2002.tb02083.x","volume":"959","author":"EA Porta","year":"2002","unstructured":"Porta, E. A. Pigments in aging: an overview. Ann. N. Y. Acad. Sci. 959, 57\u201365 (2002).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2566_CR181","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1007\/s00259-007-0709-6","volume":"35","author":"G Eichhoff","year":"2008","unstructured":"Eichhoff, G., Busche, M. A. & Garaschuk, O. In vivo calcium imaging of the aging and diseased brain. Eur. J. Nucl. Med. Mol. Imaging 35, S99\u2013S106 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2566_CR182","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/glia.20468","volume":"55","author":"A Sierra","year":"2007","unstructured":"Sierra, A., Gottfried-Blackmore, A. C., McEwen, B. S. & Bulloch, K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55, 412\u2013424 (2007).","journal-title":"Glia"},{"key":"2566_CR183","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-6688-2_12","volume":"1538","author":"S Hong","year":"2017","unstructured":"Hong, S., Wilton, D. K., Stevens, B. & Richardson, D. S. Structured illumination microscopy for the investigation of synaptic structure and function. Methods Mol. Biol. 1538, 155\u2013167 (2017).","journal-title":"Methods Mol. Biol."},{"key":"2566_CR184","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2010.01.026","volume":"140","author":"PL Greer","year":"2010","unstructured":"Greer, P. L. et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 140, 704\u2013716 (2010).","journal-title":"Cell"},{"key":"2566_CR185","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2010.09.038","volume":"143","author":"SS Margolis","year":"2010","unstructured":"Margolis, S. S. et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 143, 442\u2013455 (2010).","journal-title":"Cell"},{"key":"2566_CR186","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuron.2007.06.014","volume":"55","author":"KD Micheva","year":"2007","unstructured":"Micheva, K. D. & Smith, S. J. Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron 55, 25\u201336 (2007).","journal-title":"Neuron"},{"key":"2566_CR187","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.neuron.2010.02.025","volume":"65","author":"SE Ross","year":"2010","unstructured":"Ross, S. E. et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron 65, 886\u2013898 (2010).","journal-title":"Neuron"},{"key":"2566_CR188","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10561-008-9068-1","volume":"9","author":"HJ Waldvogel","year":"2008","unstructured":"Waldvogel, H. J. et al. The collection and processing of human brain tissue for research. Cell Tissue Bank 9, 169\u2013179 (2008).","journal-title":"Cell Tissue Bank"},{"key":"2566_CR189","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017).","journal-title":"Nature"},{"key":"2566_CR190","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"41","author":"JB Penney Jr.","year":"1997","unstructured":"Penney, J. B. Jr., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann. Neurol. 41, 689\u2013692 (1997).","journal-title":"Ann. Neurol."},{"key":"2566_CR191","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neuropsychologia.2018.08.018","volume":"119","author":"S Vez","year":"2018","unstructured":"Vez, S. et al. Auditory time perception in Huntington\u2019s disease. Neuropsychologia 119, 247\u2013252 (2018).","journal-title":"Neuropsychologia"},{"key":"2566_CR192","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","volume":"3","author":"T Vinther-Jensen","year":"2016","unstructured":"Vinther-Jensen, T. et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol. Neuroimmunol. Neuroinflamm. 3, e287 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2566_CR193","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cortex.2013.11.009","volume":"52","author":"MJ Novak","year":"2014","unstructured":"Novak, M. J. et al. White matter integrity in premanifest and early Huntington\u2019s disease is related to caudate loss and disease progression. Cortex 52, 98\u2013112 (2014).","journal-title":"Cortex"},{"key":"2566_CR194","doi-asserted-by":"publisher","first-page":"e73280","DOI":"10.1371\/journal.pone.0073280","volume":"8","author":"O Phillips","year":"2013","unstructured":"Phillips, O. et al. Tractography of the corpus callosum in Huntington\u2019s disease. PLoS ONE 8, e73280 (2013).","journal-title":"PLoS ONE"},{"key":"2566_CR195","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/cercor\/bhr360","volume":"22","author":"M Di Paola","year":"2012","unstructured":"Di Paola, M. et al. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington\u2019s disease. Cereb. Cortex 22, 2858\u20132866 (2012).","journal-title":"Cereb. Cortex"},{"key":"2566_CR196","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","volume":"41","author":"A Matusch","year":"2014","unstructured":"Matusch, A. et al. Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington\u2019s disease. Eur. J. Nucl. Med. Mol. Imaging 41, 1210\u20131220 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2566_CR197","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1167\/iovs.04-0541","volume":"45","author":"GT Prusky","year":"2004","unstructured":"Prusky, G. T., Alam, N. M., Beekman, S. & Douglas, R. M. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest. Ophthalmol. Vis. Sci. 45, 4611\u20134616 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2566_CR198","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0031-9384(00)00219-5","volume":"69","author":"VS Valentinuzzi","year":"2000","unstructured":"Valentinuzzi, V. S. et al. Locomotor response to an open field during C57BL\/6J active and inactive phases: differences dependent on conditions of illumination. Physiol. Behav. 69, 269\u2013275 (2000).","journal-title":"Physiol. Behav."},{"key":"2566_CR199","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1601-183x.2004.00069.x","volume":"3","author":"SM Hossain","year":"2004","unstructured":"Hossain, S. M., Wong, B. K. & Simpson, E. M. The dark phase improves genetic discrimination for some high throughput mouse behavioral phenotyping. Genes Brain Behav. 3, 167\u2013177 (2004).","journal-title":"Genes Brain Behav."}],"updated-by":[{"DOI":"10.1038\/s41591-023-02663-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02566-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T05:10:53Z","timestamp":1700716253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02566-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":199,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02566-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-023-02663-3","URL":"https:\/\/doi.org\/10.1038\/s41591-023-02663-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S. serves on the scientific advisory board of Annexon Biosciences and is a minor shareholder of this company. T.Y. is the chief innovation officer of Annexon Biosciences, a publicly traded biotechnology company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}